Jianmei Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jianmei Huang has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Chenyang Wang
Institute of Medical Genetics, Henan Provincial People’s Hospital, Zhengzhou University People’s Hospital, Henan University People’s Hospital, Zhengzhou, China
2 shared publications- Shixiu Liao
Institute of Medical Genetics, Henan Provincial People’s Hospital, Zhengzhou University People’s Hospital, Henan University People’s Hospital, Zhengzhou, China
2 shared publications - Zhenglong Guo
Henan Provincial Key Laboratory of Genetic Diseases and Functional Genomics, Medical Genetics Institute of Henan Province, Henan Provincial People’s Hospital, People’s Hospital of Zhengzhou University, Zhengzhou, China
2 shared publications Bingjie Mei
School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
1 shared publicationChunyu Wu
State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University
1 shared publication- Guonan Zhang
Department of Gynecologic Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China
1 shared publication
Latest Publications
- Open Access
- 15 October 2026
- Published by Springer Nature in Human Genomics
Identification of a novel IGBP1 L49F variant in X‑linked intellectual disability
- 15 October 2026
- Published by Springer Nature in Human Genomics
Open AccessIdentification of a novel IGBP1 L49F variant in X‑linked intellectual disability
- Open Access
- 30 January 2026
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 14, 1724485
The D826V point mutation in IREB2 induces lipogenesis in adipose tissues
Background: IREB2 is an RNA-binding protein that modulates cellular iron uptake and storage by regulating ferritin expression. Mutations in the IREB2 gene have been shown to induce degradation of the IREB2 protein, resulting in the upregulation of FTH1 protein expression, which contributes to iron storage. This study investigates the potential mechanism of the Ireb2 D826V/D826V mutation on lipid biosynthesis for the first time. Results: In this study, it was discovered for the first time that Ireb2 D826V/D826V mice exhibited increased body weight, hypertrophic adipocytes, iron and lipid accumulation. RNA-sequencing analysis suggests that the Ireb2 D826V/D826V mutation potentially activates pathways involved in fatty acid and triglyceride biosynthesis. This activation is evidenced by the upregulation of lipid biosynthetic genes, including Fasn , Acaca , Acly , Fgfr4 , and Egr1 , along with their corresponding protein expressions in Ireb2 D826V/D826V mice. These molecular changes occur alongside the degradation of IREB2, an increase in FTH1 expression and iron accumulation in tissues. Metabolomic analysis confirmed that the Ireb2 D826V/D826V mutation indeed elevated the levels of certain fatty acids and triglyceride components in epWAT. Moreover, in vitro experiments utilizing adipocytes confirmed that the Ireb2 D826V/D826V mutation augmented fatty acid and triglyceride biosynthesis, as well as the expression of associated proteins, contingent upon iron accumulation. Conclusion: The Ireb2 D826V/D826V mutation is linked to the degradation of IREB2, increased expression of FTH1, and iron accumulation. These molecular alterations are associated with elevated protein levels of ACACA, ACLY, FASN, EGR1, and FGFR4, which correlate with enhanced lipid biosynthesis and subsequent weight gain. This study elucidates a link between dysregulated iron storage, mediated via the IREB2-FTH1 axis, and the upregulation of key lipogenic genes, resulting in enhanced lipid biosynthesis. These findings underscore a potential relationship between iron metabolism and obesity, suggesting that iron homeostasis could serve as a valuable target for further mechanistic investigation and therapeutic development in the context of obesity.
- 30 January 2026
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 14, 1724485
Open AccessThe D826V point mutation in IREB2 induces lipogenesis in adipose tissues
Background: IREB2 is an RNA-binding protein that modulates cellular iron uptake and storage by regulating ferritin expression. Mutations in the IREB2 gene have been shown to induce degradation of the IREB2 protein, resulting in the upregulation of FTH1 protein expression, which contributes to iron storage. This study investigates the potential mechanism of the Ireb2 D826V/D826V mutation on lipid biosynthesis for the first time. Results: In this study, it was discovered for the first time that Ireb2 D826V/D826V mice exhibited increased body weight, hypertrophic adipocytes, iron and lipid accumulation. RNA-sequencing analysis suggests that the Ireb2 D826V/D826V mutation potentially activates pathways involved in fatty acid and triglyceride biosynthesis. This activation is evidenced by the upregulation of lipid biosynthetic genes, including Fasn , Acaca , Acly , Fgfr4 , and Egr1 , along with their corresponding protein expressions in Ireb2 D826V/D826V mice. These molecular changes occur alongside the degradation of IREB2, an increase in FTH1 expression and iron accumulation in tissues. Metabolomic analysis confirmed that the Ireb2 D826V/D826V mutation indeed elevated the levels of certain fatty acids and triglyceride components in epWAT. Moreover, in vitro experiments utilizing adipocytes confirmed that the Ireb2 D826V/D826V mutation augmented fatty acid and triglyceride biosynthesis, as well as the expression of associated proteins, contingent upon iron accumulation. Conclusion: The Ireb2 D826V/D826V mutation is linked to the degradation of IREB2, increased expression of FTH1, and iron accumulation. These molecular alterations are associated with elevated protein levels of ACACA, ACLY, FASN, EGR1, and FGFR4, which correlate with enhanced lipid biosynthesis and subsequent weight gain. This study elucidates a link between dysregulated iron storage, mediated via the IREB2-FTH1 axis, and the upregulation of key lipogenic genes, resulting in enhanced lipid biosynthesis. These findings underscore a potential relationship between iron metabolism and obesity, suggesting that iron homeostasis could serve as a valuable target for further mechanistic investigation and therapeutic development in the context of obesity.
- Open Access
- 31 October 2022
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 20 (1) , 1-15
Whole-cell tumor vaccines desialylated to uncover tumor antigenic Gal/GalNAc epitopes elicit anti-tumor immunity
Background: Aberrant sialoglycans on the surface of tumor cells shield potential tumor antigen epitopes, escape recognition, and suppress activation of immunocytes. α2,3/α2,6Gal- and α2,6GalNAc (Gal/GalNAc)-linked sialic acid residues of sialoglycans could affect macrophage galactose-type lectins (MGL) mediated-antigen uptake and presentation and promote sialic acid-binding immunoglobulin-like lectins (Siglecs) mediated-immunosuppression. Desialylating sialoglycans on tumor cells could present tumor antigens with Gal/GalNAc residues and overcome glyco-immune checkpoints. Thus, we explored whether vaccination with desialylated whole-cell tumor vaccines (DWCTVs) triggers anti-tumor immunity in ovarian cancer (OC). Methods: Sialic acid (Sia) and Gal/GalNAc residues on OC A2780, OVCAR3, and ID8 cells treated with α2-3 neuraminidase (α2-3NA) and α2-6NA, and Sigec-9 or Siglec-E and MGL on DCs pulsed with desialylated OC cells were identified using flow cytometry (FCM); RT-qPCR determined IFNG expression of T cells, TRBV was sequenced using Sanger sequencing and cytotoxicity of αβ T cells was measured with LDH assay; Anti-tumor immunity in vivo was validated via vaccination with desialylated whole-cell ID8 vaccine (ID8 DWCTVs). Results: Gal/GalNAc but not Sia residues were significantly increased in the desialylated OC cells. α2-3NA-modified DWCTV increased MGL but decreased Siglec-9 or Siglec E expression on DCs. MGLbright/Siglec-9dim DCs significantly up-regulated IFNG expression and CD4/CD8 ratio of T cells and diversified the TCR repertoire of αβ T-cells that showed enhanced cytotoxic activity. Vaccination with α2-3NA-modified ID8 DWCTVs increased MGLbright/Siglec-Edim DCs in draining lymph nodes, limited tumor growth, and extended survival in tumor-challenged mice. Conclusion: Desialylated tumor cell vaccine could promote anti-tumor immunity and provide a strategy for OC immunotherapy in a clinical setting.
- 31 October 2022
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 20 (1) , 1-15
Open AccessWhole-cell tumor vaccines desialylated to uncover tumor antigenic Gal/GalNAc epitopes elicit anti-tumor immunity
Background: Aberrant sialoglycans on the surface of tumor cells shield potential tumor antigen epitopes, escape recognition, and suppress activation of immunocytes. α2,3/α2,6Gal- and α2,6GalNAc (Gal/GalNAc)-linked sialic acid residues of sialoglycans could affect macrophage galactose-type lectins (MGL) mediated-antigen uptake and presentation and promote sialic acid-binding immunoglobulin-like lectins (Siglecs) mediated-immunosuppression. Desialylating sialoglycans on tumor cells could present tumor antigens with Gal/GalNAc residues and overcome glyco-immune checkpoints. Thus, we explored whether vaccination with desialylated whole-cell tumor vaccines (DWCTVs) triggers anti-tumor immunity in ovarian cancer (OC). Methods: Sialic acid (Sia) and Gal/GalNAc residues on OC A2780, OVCAR3, and ID8 cells treated with α2-3 neuraminidase (α2-3NA) and α2-6NA, and Sigec-9 or Siglec-E and MGL on DCs pulsed with desialylated OC cells were identified using flow cytometry (FCM); RT-qPCR determined IFNG expression of T cells, TRBV was sequenced using Sanger sequencing and cytotoxicity of αβ T cells was measured with LDH assay; Anti-tumor immunity in vivo was validated via vaccination with desialylated whole-cell ID8 vaccine (ID8 DWCTVs). Results: Gal/GalNAc but not Sia residues were significantly increased in the desialylated OC cells. α2-3NA-modified DWCTV increased MGL but decreased Siglec-9 or Siglec E expression on DCs. MGLbright/Siglec-9dim DCs significantly up-regulated IFNG expression and CD4/CD8 ratio of T cells and diversified the TCR repertoire of αβ T-cells that showed enhanced cytotoxic activity. Vaccination with α2-3NA-modified ID8 DWCTVs increased MGLbright/Siglec-Edim DCs in draining lymph nodes, limited tumor growth, and extended survival in tumor-challenged mice. Conclusion: Desialylated tumor cell vaccine could promote anti-tumor immunity and provide a strategy for OC immunotherapy in a clinical setting.